American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV. 

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter 

Articles

Cellular therapies have the potential to make a meaningful difference for patients with neurological disorders, if used correctly.

Cell Therapies Offer Hope But Are Often Misused

IncobotulinumtoxinA significantly reduced unstimulated salivary flow rate for patients with sialorrhea.

IncobotulinumtoxinA Reduces Sialorrhea Across Neurological Disorders

Patisiran maintained improvements in mNIS+7 and rapidly halted neurologic disease progression in hATTR amyloidosis.

Patisiran Shows Sustained Improvements in Disease Progression for hATTR Amyloidosis

Subcutaneous immunoglobulin is an effective and well-tolerated alternative to intravenous immunoglobulin for myasthenia gravis.
 

Subcutaneous Immunoglobulin Effective Alternative to Intravenous for Myasthenia Gravis

Eculizumab showed sustained activity and tolerability through 3 years for generalized myasthenia gravis.
 

American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

Cell Therapies Offer Hope But Are Often Misused

IncobotulinumtoxinA Reduces Sialorrhea Across Neurological Disorders

Patisiran Shows Sustained Improvements in Disease Progression for hATTR Amyloidosis

Subcutaneous Immunoglobulin Effective Alternative to Intravenous for Myasthenia Gravis

Eculizumab's Myasthenia Gravis Benefits Sustained in Long-Term Extension Study